|
|
News Breaks
|
November 10, 2009
|
| 09:21 EDT |  | BIIB |
| theflyonthewall.com: | Biogen Idec shares more than price in Tysabri challenges, says Leerink | | Leerink's survey of neurologists indicated the majority of doctors are taking the updated PML rates for Tysabri "in stride." The firm continues to believe shares of Biogen are more than pricing in the drug's challenges and it maintains an Outperform rating on the stock. :theflyonthewall.com |
|
|
News For BIIB From The Last 14 Days Check below for free stories on BIIB the last two weeks.
There are 11 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 13, 2012
|
| 16:22 EDT |  | BIIB |
|
|
February 10, 2012
|
| 10:01 EDT |  | BIIB |
| | 09:27 EDT |  | BIIB |
| | 06:36 EDT | | BIIB |
|
|
February 9, 2012
|
| 16:27 EDT | | BIIB |
| theflyonthewall.com: | Leerink's biotech and pharmaceuticals analysts hold a conference call | | Biotech Analysts Schimmer and Liang, along with Pharmaceuticals Analyst Fernandez, review the reimbursement process for drugs in France on an Analyst/Industry conference call. Relevant covered companies ACOR, AMGN, AMLN, AUXL, BIIB, BMY, GILD, HGSI, ITMN, JNJ, NVS, PFE and VRTX may be included on the Analyst/Industry conference call to be held on February 10 at 11 am. :theflyonthewall.com |
|
|
February 6, 2012
|
| 08:22 EDT |  | BIIB |
|
|
January 31, 2012
|
| 11:21 EDT | | BIIB |
| | 07:03 EDT |  | BIIB |
| theflyonthewall.com: | Biogen reports Q4 global in-market sales of TYSABRI $380M | | Based upon data available to us through the TOUCH® prescribing program and other third-party sources, as of the end of December 2011, the company estimates that approximately 64,400 patients were on commercial and clinical TYSABRI therapy worldwide, and that cumulatively approximately 95,300 patients have ever been treated with TYSABRI in the post-marketing setting. :theflyonthewall.com |
| | 07:03 EDT | | BIIB |
| | 07:03 EDT | | BIIB |
| | 07:02 EDT | | BIIB |
|
|
|
|
|
Subscribe for More Information